Skip to main content

Advertisement

Fig. 7 | BMC Cancer

Fig. 7

From: Utilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug

Fig. 7

Simulation of CNOB dose administrations and predicted tumor growth inhibition. Based on the PK parameters estimates from noncompartmental analysis of single (3.3 mg/kg) dose of CNOB, and tumor growth data (Fig. 6), a combined PK/PD model was constructed which included a 2 compartment iv model linked with an inhibitory Emax model. Simulation predicted plasma CNOB concentrations (a) and corresponding tumor growth curves (b) after the indicated daily doses of CNOB. Circles represent original tumor burden data from Fig. 6

Back to article page